FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLET OF TRIMETAZIDINE DIHYDROCHLORIDE

Hemant Sankhala; Bharat Patil; Paresh Mandore; M.P.Patil; V.R Patil

Hemant Sankhala T.V.E.S’s Hon’ble Loksevak Madhukarrao Chaudhari College of Pharmacy, Faizpur-425503
Bharat Patil T.V.E.S’s Hon’ble Loksevak Madhukarrao Chaudhari College of Pharmacy, Faizpur-425503
Paresh Mandore T.V.E.S’s Hon’ble Loksevak Madhukarrao Chaudhari College of Pharmacy, Faizpur-425503
M.P.Patil T.V.E.S’s Hon’ble Loksevak Madhukarrao Chaudhari College of Pharmacy, Faizpur-425503
V.R Patil T.V.E.S’s Hon’ble Loksevak Madhukarrao Chaudhari College of Pharmacy, Faizpur-425503

Keywords: Anti-hypertensive drugs, Trimetazidine dihydrochloride etc

Abstract

The anti-hypertensive drugs will dominate the global cardiovascular market with a market share of nearly 50%.1 A common problem associated with Trimetazidine dihydrochloride conventional therapy is that of “dosedumping” or “dose loading” resulting in increased risk of toxicity. Conventional therapy is also associated with a high incidence of gastro intestinal side effects and seen in about 30% patients. However, a sustained release Trimetazidine dihydrochloride formulation will release a smaller amount of drug and hence ensure a decrease in side effects.